Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roberts Pharmaceutical

This article was originally published in The Tan Sheet

Executive Summary

Signs "two-step" agreement to acquire line of 21 Rx and OTC drugs from Glaxo Canada. The first part of the deal, which covers products purchased outright, includes five OTCs: Betnesol topical anti-inflammatory steroid, Prenavite prenatal vitamin supplement, bacitracin zinc ointment, Glaxal moisturizing cream and Barriere hand cream. Under part two of the deal, Roberts will market and promote certain Glaxo products in Canada including the Rx antihypertensive Trandate, the OTC dermatological Betnovate, and Dequadin OTC throat lozenges. Eatontown, N.J.-based Roberts said it has the option to purchase these products "subject to certain conditions".
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS081451

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel